Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Non-Current Assets: 2012-2025

Historic Other Non-Current Assets for Agios Pharmaceuticals (AGIO) over the last 12 years, with Sep 2025 value amounting to $3.9 million.

  • Agios Pharmaceuticals' Other Non-Current Assets fell 3.11% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year decrease of 3.11%. This contributed to the annual value of $4.7 million for FY2024, which is 16.44% up from last year.
  • Agios Pharmaceuticals' Other Non-Current Assets amounted to $3.9 million in Q3 2025, which was down 0.30% from $3.9 million recorded in Q2 2025.
  • Agios Pharmaceuticals' 5-year Other Non-Current Assets high stood at $4.7 million for Q4 2024, and its period low was $2.9 million during Q2 2021.
  • In the last 3 years, Agios Pharmaceuticals' Other Non-Current Assets had a median value of $4.1 million in 2024 and averaged $4.1 million.
  • The largest annual percentage gain for Agios Pharmaceuticals' Other Non-Current Assets in the last 5 years was 114.81% (2021), contrasted with its biggest fall of 93.94% (2021).
  • Over the past 5 years, Agios Pharmaceuticals' Other Non-Current Assets (Quarterly) stood at $2.9 million in 2021, then spiked by 36.41% to $4.0 million in 2022, then climbed by 2.55% to $4.1 million in 2023, then increased by 16.44% to $4.7 million in 2024, then dropped by 3.11% to $3.9 million in 2025.
  • Its Other Non-Current Assets was $3.9 million in Q3 2025, compared to $3.9 million in Q2 2025 and $4.7 million in Q1 2025.